U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H25NO3
Molecular Weight 315.4067
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MITIGLINIDE

SMILES

OC(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)CC3=CC=CC=C3

InChI

InChIKey=WPGGHFDDFPHPOB-BBWFWOEESA-N
InChI=1S/C19H25NO3/c21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13H2,(H,22,23)/t15-,16+,17-/m0/s1

HIDE SMILES / InChI

Molecular Formula C19H25NO3
Molecular Weight 315.4067
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Mitiglinide is a drug for the treatment of type 2 diabetes currently marked under tradename Glufast. Glufast® is available as the tablet for oral use, containing 5 mg or 10 mg of Mitiglinide calcium hydrate. The recommended dose is 10 mg three times daily just before each meal (within 5 minutes). Mitiglinide was approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on January 29, 2004, and is currently co-marketed in Japan by Kissei and Takeda. Mitiglinide is a rapid-acting insulin secretion-stimulating agent, its belongs to the meglitinide (glinide) class of blood glucose-lowering drugs. Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels in pancreatic beta-cells.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
4.0 nM [IC50]
3.0 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Glufast

Approved Use

Unknown

Launch Date

2004
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
683.2 μg/L
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered: Metformin
MITIGLINIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
704 μg/L
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered: Metformin
MITIGLINIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
915.1 μg × h/L
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered: Metformin
MITIGLINIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1025.5 μg × h/L
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered: Metformin
MITIGLINIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.19 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered: Metformin
MITIGLINIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.67 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered: Metformin
MITIGLINIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Effects of S 21403 on hormone secretion from isolated rat pancreas at different glucose concentrations.
2002 Dec 5
[Mitiglinide (KAD-1229)].
2002 Sep
[Nateglinide and mitiglinide].
2003 Jul
[Pharmacological and clinical profile of mitiglinide calcium hydrate (Glufast), a new insulinotropic agent with rapid onset].
2004 Oct
[Effects of mitiglinide in treatment of impaired glucose tolerance].
2005 Feb
[Glinide(s), sulfonylurea(s)].
2006 Nov
Long-term effect of combination therapy with mitiglinide and once daily insulin glargine in patients who were successfully switched from intensive insulin therapy in short-term study.
2007 Feb
High-performance liquid chromatography-electrospray ionization mass spectrometry determination of mitiglinide in human plasma and its pharmacokinetics.
2007 Feb
Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum.
2007 Jul
Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases.
2007 Jun 1
Mitiglinide, a novel oral hypoglycemic agent, preserves the cardioprotective effect of ischemic preconditioning in isolated perfused rat hearts.
2007 May
Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus.
2007 Nov
Quantitative determination of mitiglinide in human plasma by ultra-performance liquid chromatography/electrospray ionization tandem mass spectrometry.
2008 Jun 1
Ca(2+) channels on the move.
2009 Dec 29
Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China.
2009 May-Jun
Effect of mitiglinide on Streptozotocin-induced experimental type 2 diabetic rats: a urinary metabonomics study based on ultra-performance liquid chromatography-tandem mass spectrometry.
2009 Nov 1
Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis.
2010
Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis.
2010 Feb
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: https://clinicaltrials.gov/ct2/show/NCT02143765
The recommended dose is 10 mg three times daily just before each meal (within 5 minutes).
Route of Administration: Oral
3T3-L1 cells were challenged during the first 4 days of differentiation with Mitiglinide at 1, 10 and 100 mkM. Seven days after the induction of 3T3-L1 cells, oil red O staining was used to detect triglyceride accumulation in 3T3-L1 cells.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:26:03 GMT 2025
Edited
by admin
on Mon Mar 31 18:26:03 GMT 2025
Record UNII
D86I0XLB13
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MITIGLINIDE
INN   MART.   MI   WHO-DD  
INN  
Official Name English
MITIGLINIDE [MI]
Preferred Name English
(-)-(2S,3A,7A-CIS)-A-BENZYLHEXAHYDRO-.GAMMA.-OXO-2-ISOINDOLINEBUTYRIC ACID
Common Name English
mitiglinide [INN]
Common Name English
Mitiglinide [WHO-DD]
Common Name English
MITIGLINIDE [MART.]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C98079
Created by admin on Mon Mar 31 18:26:03 GMT 2025 , Edited by admin on Mon Mar 31 18:26:03 GMT 2025
WHO-VATC QA10BX08
Created by admin on Mon Mar 31 18:26:03 GMT 2025 , Edited by admin on Mon Mar 31 18:26:03 GMT 2025
WHO-ATC A10BX08
Created by admin on Mon Mar 31 18:26:03 GMT 2025 , Edited by admin on Mon Mar 31 18:26:03 GMT 2025
Code System Code Type Description
PUBCHEM
121891
Created by admin on Mon Mar 31 18:26:03 GMT 2025 , Edited by admin on Mon Mar 31 18:26:03 GMT 2025
PRIMARY
INN
7710
Created by admin on Mon Mar 31 18:26:03 GMT 2025 , Edited by admin on Mon Mar 31 18:26:03 GMT 2025
PRIMARY
DRUG BANK
DB01252
Created by admin on Mon Mar 31 18:26:03 GMT 2025 , Edited by admin on Mon Mar 31 18:26:03 GMT 2025
PRIMARY
SMS_ID
100000080668
Created by admin on Mon Mar 31 18:26:03 GMT 2025 , Edited by admin on Mon Mar 31 18:26:03 GMT 2025
PRIMARY
EVMPD
SUB08999MIG
Created by admin on Mon Mar 31 18:26:03 GMT 2025 , Edited by admin on Mon Mar 31 18:26:03 GMT 2025
PRIMARY
FDA UNII
D86I0XLB13
Created by admin on Mon Mar 31 18:26:03 GMT 2025 , Edited by admin on Mon Mar 31 18:26:03 GMT 2025
PRIMARY
CAS
145375-43-5
Created by admin on Mon Mar 31 18:26:03 GMT 2025 , Edited by admin on Mon Mar 31 18:26:03 GMT 2025
PRIMARY
DRUG CENTRAL
1818
Created by admin on Mon Mar 31 18:26:03 GMT 2025 , Edited by admin on Mon Mar 31 18:26:03 GMT 2025
PRIMARY
MERCK INDEX
m7566
Created by admin on Mon Mar 31 18:26:03 GMT 2025 , Edited by admin on Mon Mar 31 18:26:03 GMT 2025
PRIMARY Merck Index
MESH
C087255
Created by admin on Mon Mar 31 18:26:03 GMT 2025 , Edited by admin on Mon Mar 31 18:26:03 GMT 2025
PRIMARY
WIKIPEDIA
MITIGLINIDE
Created by admin on Mon Mar 31 18:26:03 GMT 2025 , Edited by admin on Mon Mar 31 18:26:03 GMT 2025
PRIMARY
EPA CompTox
DTXSID4048303
Created by admin on Mon Mar 31 18:26:03 GMT 2025 , Edited by admin on Mon Mar 31 18:26:03 GMT 2025
PRIMARY
NCI_THESAURUS
C81699
Created by admin on Mon Mar 31 18:26:03 GMT 2025 , Edited by admin on Mon Mar 31 18:26:03 GMT 2025
PRIMARY
ChEMBL
CHEMBL471498
Created by admin on Mon Mar 31 18:26:03 GMT 2025 , Edited by admin on Mon Mar 31 18:26:03 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY